FAK2 Inhibitors
2 drugsAbout FAK2
Focal Adhesion Kinase 2 (FAK2) is a non-receptor tyrosine kinase involved in cell adhesion, migration, and survival. It plays a role in cell signaling pathways relevant to cancer progression.
FAK2 is a compelling oncology target due to its involvement in tumor dysregulation. Currently, there is no genetic evidence directly linking FAK2 to specific diseases.
FAK2 is targeted by one FDA-approved drug, LORBRENA (Pfizer), a small molecule used in oncology. This single approval underscores FAK2's potential as a therapeutic intervention point.
Top FAK2 Drugs
Pfizer is the only company with an approved FAK2-targeting drug.
The lack of competitors indicates high barriers to entry or untapped market potential.
FAK2 Drug Modality Landscape
Modalities
Routes of Administration
FAK2 is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
FAK2 Clinical Trials 51 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FAK2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 8 | 3 | 6 | 73% |
| Phase 2 | 22 | 3 | 3 | 16 | 50% |
| Phase 3 | 6 | 2 | 0 | 4 | 100% |
| Phase 4 | 6 | 2 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FAK2 Drug Approval Timeline (2018 - 2025)
LORBRENA was first approved in 2018 and remains the most recent approval.
The single approval in 2018 suggests the field is nascent, with room for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FAK2. A trial counts if an approved drug acting on FAK2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.